Keitaro Yokoyama - Publications

Corrigendum to 'Determination of a serum 25-hydroxyvitamin D reference ranges in Japanese adults using fully automated liquid chromatography tandem mass spectrometry' [J. Nutr. 2023; 153: 1253-1264].

Journal: The Journal of nutrition

Published: February 10, 2026

Temporal trends in myocardial ischemia risk estimated from 12-lead electrocardiograms using deep learning in individuals with suspected cancer during health checkups.

Journal: Cardio-oncology (London, England)

Published: August 12, 2025

The epidemiology of encapsulating peritoneal sclerosis in an era of biocompatible neutral peritoneal dialysis solution in Japan.

Journal: Clinical and experimental nephrology

Published: April 21, 2025

Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis.

Journal: Renal failure

Published: September 04, 2024

Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study.

Journal: American journal of nephrology

Published: June 13, 2024

Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.

Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Published: December 06, 2022

Determination of a Serum 25-Hydroxyvitamin D Reference Ranges in Japanese Adults Using Fully Automated Liquid Chromatography-Tandem Mass Spectrometry.

Journal: The Journal of nutrition

Published: November 21, 2022

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties.

Journal: Clinical pharmacokinetics

Published: May 04, 2022

Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric acid secretion inhibitors in patients with chronic kidney disease: a retrospective post hoc analysis.

Journal: International urology and nephrology

Published: February 16, 2022

Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.

Journal: Clinical and experimental nephrology

Published: November 08, 2021

Clinical feasibility of transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.

Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Published: August 06, 2021

Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.

Journal: BMC nephrology

Published: May 10, 2021